Skip to main content
[Preprint]. 2023 Dec 21:rs.3.rs-3712137. [Version 1] doi: 10.21203/rs.3.rs-3712137/v1

Figure 6: Runx2 overexpression as a novel strategy for enhancement of naïve-derived CD8+ CAR T cell potency and resistance to dysfunction.

Figure 6:

6A-B: Cotransduction of memory (A) or naïve (B) CD8+ T cells with CAR and pMIG-Empty, pMIG-BATF, or pMIG-JUN. For 6C-F & I-L, Rag1−/− mice were given leukemia on day −3, followed by 1e5 pMIG-Runx2 or pMIG-Empty co-transduced CAR8 on day 0. Bone marrow was analyzed by flow cytometry on day 11 post-CAR. 6C & D: CAR T cell and leukemia proportions for naïve (C) and memory-derived (D) CAR T cells cotransduced with BATF, JUN or pMIG control. 6E & F: Proportion of CAR T cells displaying PD1+/TOX+ phenotype. 6G-H: Cotransduction of memory (G) or naïve (H) CD8+ T cells with CAR and pMIG-Empty or pMIG-Runx2 and intracellular staining for Runx2. 6I & J: CAR T cell and leukemia proportions for naïve (C) and memory-derived (D) CAR T cells cotransduced with RUNX2 or pMIG control. 6K & L: Proportion of CAR T cells displaying PD1+/TOX+ phenotype. Data in 6A,B,G & H are representative of 3–4 independent experiments. Data in 6C-F are from 1 experiment with n=5 mice per condition. Data in 6I-L are from 2 pooled, independent experiments with n=9 mice per condition. Data represent mean +/− SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.